
Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Your AI-Trained Oncology Knowledge Connection!

UT Southwestern Medical Center

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Dr Zeidan highlights ongoing clinical trials for treatment of higher-risk MDS.

Dr Brunner presents updated data on the treatment of lower-risk MDS with IRAK1/IRAK4 inhibitors.

Dr Carraway discusses data updates on oral hypomethylating agents (HMAs) decitabine and azacitidine for the treatment of lower-risk MDS.

Dr Zeidan shares data presented at ASCO 2023 on the first-in-class agent Imetelstat for the treatment of lower-risk MDS.

Rami Komrokji, MD, summarizes data presented at ASCO 2023 from the COMMANDS trial on the role of luspatercept in lower-risk MDS.

Dr Madanat reviews data from an abstract presented at ASCO 2023 on the outcomes of ESA therapy in patients with SF3B1-mutated lower-risk MDS.

The panel discusses the patient profile of a man with lower-risk MDS and how they would have approached treatment in their practice.

Yazan Madanat, MD, presents the patient profile of a transfusion-dependent 79-year-old man with lower-risk MDS and a KRAS mutation.

Panelists review the presented patient profile and shares how they would have approached treatment.

Dr Brunner presents the patient profile of a 75-year-old man with transfusion-dependent, lower-risk MDS and symptomatic anemia.

Andrew Brunner, MD, reviews the available second-line treatment options for lower-risk MDS with symptomatic anemia.

Dr Madanat defines erythropoiesis-stimulating agent (ESA) treatment failure in lower-risk MDS with symptomatic anemia and describes his approach to monitoring patients.

The panel shares at what point they decide to start treatment for patients with lower-risk MDS and symptomatic anemia.

Yazan Madanat, MD, details the available options for first-line treatment of patients with lower-risk MDS and symptomatic anemia.

Amer Zeidan, MBBS, MHS, explains risk stratification in MDS, how the process has evolved over time, and the guidelines he typically follows.

Hetty Carraway, MD, reviews how MDS is diagnosed and the common symptoms that patients who have MDS may present with.

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.

Drs Madanat and Sekeres comment on the importance of quality of life and patient perspective in the selection of MDS treatment.

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, highlight unmet needs in the treatment of patients with high-risk MDS.

Experts in the treatment of MDS explore clinically meaningful treatment endpoints, including complete responses, bone marrow complete responses, and overall survival outcomes in MDS.

Drs Madanat and Sekeres discuss specific patient characteristics affecting selection of treatment for MDS.

Yazan Madanat, MD, explores toxicity and adverse events impacting treatment selection for patients with MDS.

Mikkael A. Sekeres, MD, discusses his approach to treatment in patients with high-risk MDS incorporating efficacious clinical trial data.

Experts in the treatment of MDS discuss the clinical implications and treatment selection for patients with high-risk MDS.

Mikkael A. Sekeres, MD, explores prognostic and predictive factors inherent to high-risk MDS, including age and molecular abnormalities.

Yazan Madanat, MD, discusses available MDS risk assessment tools and provides insight into his preferred clinical assessment methods.

Drs Madanat and Sekeres comment on the various risk stratification factors and prognostic criteria used in the classification of MDS disease.

Yazan Madanat, M.D and Mikkael A. Sekeres, M.D. discuss considerations in the classification of myelodysplastic syndrome taking into account disease heterogeneity.

Published: August 17th 2023 | Updated:

Published: September 9th 2021 | Updated:

Published: August 12th 2021 | Updated:

Published: August 10th 2023 | Updated:

Published: August 10th 2023 | Updated:

Published: September 9th 2021 | Updated: